La cadena de opciones muestra datos clave de las opciones de acciones de Cognition Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Cognition Therapeutics..

Cognition Therapeutics (NASDAQ:CGTX) Bolsa, Cadena de Opciones

Cognition Therapeutics

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics Inc

News

Trading Ideas

GOOGL

LBRDA

RIVN

Soros Fund Management 13F Shows Decreased Stake In Rivian Automotive Convertible Notes By 21% To $155.9M In Principal; Decreased Stake In Wayfair Convertible Notes By 11% To $119.5M In Principal; Decreased Stake In Liberty Broadband Corp By 19% To 1,119,893 Shares; Decreased Stake In Alphabet Class A By 43% To 517,890 Shares; Decreased Put Position In Ishares IBoxx High Yield Corporate Bond ETF By 40% To 1,500,000 Shares

Discover Financial Reports $100.7B In Credit Card Loans As Of October 2024, Up From $98.7B YoY; Average Balances Remain Stable At $100.2B; Net Principal Charge-Off Rate Drops To 4.31% With Disaster Relief Impact, Though Up From 4.42% YoY; Delinquency Rate Rises Slightly To 3.87%

Management

Zillow Group Appoints Jun Choo As COO

Offerings

GYRE

Gyre Therapeutics Files For Up To $150M Mixed Shelf

WIIM

IZEA

IZEA Worldwide shares are trading lower after the company reported worse-than-expected Q3 financial results.

BIO-key Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKYI#NASDAQ">BKYI</a>) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.58) by 32.76 percent.

Earnings

Earnings Beats

BKYI

BIO-key Intl Q3 2024 Adj EPS $(0.39) Beats $(0.58) Estimate

TFFP

TFF Pharmaceutical shares are trading lower after the company announced it will wind down its operations.

Enveric Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.52) by 53.85 percent.

ENVB

Enveric Biosciences Q3 2024 GAAP EPS $(0.24) Beats $(0.52) Estimate

AKYA

Akoya Biosciences shares are trading lower after the company reported worse-than-expected Q3 financial results.

DOCN

OKTA

Soros Fund Management 13F Shows Increased Put Position In SPDR S&P 500 ETF By 608% To 2,123,000 Shares; Increased Stake In Ishares Financial Select Sector SPDR ETF By 22,720% To 2,800,000 Shares; Increased Stake In JD.com By 114% To 2,730,000 Shares; Increased Stake In Okta Convertible Notes By 75% To $79.1M In Principal; Increased Stake In DigitalOcean Convertible Notes By 302% To $116.5M In Principal

Buybacks

Primerica Board Authorizes $450M Share Repurchase Program To Occur Through December 31, 2025

XPON

Expion360 shares are trading lower after the company reported a year-over-year decline in Q3 revenue results.

Asset Sales

BLFS

BioLife Solutions Sells Subsidiary, Arctic Solutions, For $6.1M

BENF

Beneficient Q2 2025 Revenue $8.6M Vs $(42.8M) YoY

Chardan Capital analyst Keay Nakae maintains Silence Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLN#NASDAQ">SLN</a>) with a Buy and maintains $55 price target.

Price Target

Analyst Ratings

Chardan Capital Maintains Buy on Silence Therapeutics, Maintains $55 Price Target

DBGI

DBGIW

Digital Brands Group shares are trading lower after the company reported worse-than-expected Q3 EPS results and a year-over-year decline in Q3 revenue.

As the U.S. prepares for what could be a defining legislative session for digital assets, expectations are mounting around potential <a href="https://www.benzinga.com/topic/crypto-regulations">shifts in crypto regulation</a>. 
Robert Leshner, CEO and co-founder of Superstate sees this as a turning point, with Congress possibly advancing long-awaited laws to provide clarity in the industry. 
Speaking ahead of the <a href="https://benzinga.swoogo.com/digital-assets/6342807">Benzinga Future of Digital Assets event</a>, Leshner shared his outlook on what might come next.
See Also: <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41984825/trump-rally-fades-as-investors-await-powells-remarks-bitcoin-drops-below-90000-whats-driving-markets-thursday">Trump Rally Fades As Investors Await Powell&#8217;s Remarks, Bitcoin Drops Below $90,000: What&#8217;s Driving Markets Thursday?</a>
<h3 class="wp-block-heading">A New Framework for Digital Assets</h3>
With the prospect of a Congress more favorable to digital assets, Leshner anticipates that lawmakers will focus on three core areas: a framework for stablecoins, structured definitions for digital assets, and repealing the SEC's SAB-121 guidance on crypto custody. 
He pointed out the impact of these potential regulations, explaining that they could finally end a "decade of legal grays" and replace it with "black and white rules" that would allow the industry to expand within a clear legal structure.
<figure class="wp-block-image size-full"><a href="https://benzinga.swoogo.com/digital-assets/6342807"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/13235418/905735A6-57D3-4874-9AA1-75D037842DB3-1-13.gif" alt="" class="wp-image-646877" /></a></figure>
<h3 class="wp-block-heading">Addressing Stablecoins and Custody Rules</h3>
One priority on the legislative horizon is a stablecoin bill that would establish guidelines for stablecoins in the U.S. The proposed law aims to clarify the issuance and management of stablecoins, which have become widely used in digital transactions. 
Leshner also emphasized the potential impact of repealing the SEC's SAB-121 guidance, which has restricted crypto custody by placing complex accounting requirements on crypto-related firms. Removing these restrictions, he believes, would open new possibilities for digital asset custody services in the U.S.
<h3 class="wp-block-heading">Defining Crypto Assets</h3>
Leshner highlighted the importance of clear definitions for digital assets, noting that confusion around terminology has long been a barrier for the industry. Proposed measures such as FIT21 aim to categorize digital assets, creating a structured approach that could aid mainstream adoption. Leshner views these definitions as essential for aligning crypto with existing financial regulations, creating a foundation for the industry to grow.
As Leshner prepares to speak at the <a href="https://benzinga.swoogo.com/digital-assets/6342807">Benzinga Future of Digital Assets</a> event, his perspective offers insight into how upcoming legislation could reshape the future of digital finance in the U.S.
<hr class="wp-block-separator has-alpha-channel-opacity" />
As the digital asset market continues to mature, the convergence of regulatory shifts, M&amp;A activities, and adoption trends will define the future of this dynamic field.&nbsp;<a href="https://www.benzinga.com/digital-assets" target="_blank" rel="noreferrer noopener">Benzinga's Future of Digital Assets</a>&nbsp;event in New York City this November will provide industry leaders and investors with a platform to explore these developments further, offering insights into the evolving regulatory environment and the latest market dynamics.
Image via Unsplash

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Events

Exclusives

Interview

Could New Legislation Finally Bring Clarity To US Crypto Rules? Industry Expert Weighs In

MCHP

Soros Fund Management 13F Shows Added Put Position In SPDR S&P 500 ETF With 2,123,000 Shares; Added Stake In Smurfit Westrock With 6,896,971 Shares; Added Put Position In Ishares Russell 2000 ETF With 800,000 Shares; Added Stake In Microchip Technology Convertible Notes With $130.3M In Principal;  Added Stake In Liberty Broadband Corp With 1,119,893 Shares; Added Stake In AstraZeneca With 2,652,771 Shares

SPAI

Safe Pro Group Q3 Revenue $330.756K Up From $163.547K YoY

IPower shares are trading lower after the company reported worse-than-expected Q1 financial results.

Cognition Therapeutics (CGTX) just unveiled an update. Cognition Therapeutics, Inc. has prepared a presentation for investors, analysts, and other ...

Cognition Therapeutics Shares Investor Presentation Update

Cognition Therapeutics ( ($CGTX) ) has shared an update. Cognition Therapeutics, Inc. is engaging investors with a presentation that outlines their...

Cognition Therapeutics Highlights CT1812 Potential in CNS Disorders

Warning: CGTX is at high risk of performing badly

Cognition Therapeutics (CGTX) has released a new Conversations video podcast episode. The new episode, which has been launched during DLB Awareness...

Cognition Therapeutics releases new episode of 'Conversations' podcast

Cognition Therapeutics (CGTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju...

Positive Buy Rating Reaffirmed for Cognition Therapeutics Amid Promising Alzheimer's Drug Data

Oppenheimer analyst Jay Olson maintained a Buy rating on Cognition Therapeutics (CGTX – Research Report) yesterday and set a price target of $9.00....

Cognition Therapeutics (CGTX) Gets a Buy from Oppenheimer

"In the third quarter and recent weeks Cognition Therapeutics (CGTX) achieved one of the most important milestones in its history as the Phase 2 SH...

Cognition Therapeutics reports Q3 EPS (25c), consensus (22c)

Cash and cash equivalents as of September 30, 2024 were approximately $22.0 million and total grant funds remaining from the NIA were $53.6 million...

Cognition Therapeutics sees cash runway into 2Q25

Cognition Therapeutics GAAP EPS of -$0.25

Cognition Therapeutics, Inc. ( ($CGTX) ) has released its Q3 earnings. Here is a breakdown of the information Cognition Therapeutics, Inc. presente...

Cognition Therapeutics Reports Promising Q3 2024 Results

CGTX

Health Care

Press Releases

Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease

Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences

Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia

Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference

General

Cognition Therapeutics Releases New Episode of "Conversations" Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)

Analyses from Cognition's Positive Phase 2 'SHINE' Study of CT1812 in Mild-to-Moderate Alzheimer's Disease will be Presented in a Podium Presentation at CTAD

Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD

Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD

Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum

Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update

Comments

Cognition Therapeutics

Cognition Therapeutics (CGTX) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL